Overview

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hangzhou Sciwind Biosciences Co., Ltd.